ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/CD38
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/CD38
24
trial(s) found.
NCT07764978
Haem
Phase 3
Recruiting
Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (
DURGA-5
)
autologous CAR-T-cell therapy,BCMA/CD19-targeting
+ anti-CD38 monoclonal antibody
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07728188
Haem
Phase 3
Not yet recruiting
A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM) (
M22-538
)
bispecific T-cell engager,BCMA-targeting
immunomodulatory imide drug
+ anti-CD38 monoclonal antibody
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT07681596
Haem
Phase 1 / Phase 2
Recruiting
A Modular, Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Efficacy of AZD4045, an Allogeneic Chimeric Antigen Receptor-T Cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (
D7540C00001
)
allogeneic CAR-T-cell therapy,BCMA-targeting
+ anti-CD38 monoclonal antibody
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3002 - East Melbourne - Epworth Freemasons
NCT07477587
Haem
Phase 1
Recruiting
A Randomized, Double-blind, Parallel-controlled Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO\xAE in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (
HLX15-SC-NDMM-001
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
WA
6005 - West Perth - Perth Blood Institute
NCT07391657
Haem
Phase 3
Recruiting
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma. (
DURGA-4
)
autologous CAR-T-cell therapy,BCMA/CD19-targeting
+ anti-CD38 monoclonal antibody
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07222761
Haem
Phase 3
Recruiting
An Open-Label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab Plus Carfilzomib Versus Standard of Care Combination Regimens in Patients With Relapsed/Refractory Multiple Myeloma (
LINKER-MM5
)
bispecific T-cell engager,BCMA-targeting
proteasome inhibitor
+ anti-CD38 monoclonal antibody
Multiple myeloma
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Gold Coast University Hospital
NCT06953960
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma (
M25-275
)
Bcl2 inhibitor
+ anti-CD38 monoclonal antibody
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
NCT06932562
Haem
Phase 3
Recruiting
A Randomized, Open-Label, Controlled Phase 3 Study of Comparing Daratumumab, Lenalidomide and Dexamethasone Induction Followed by Linvoseltamab Versus Continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients (
EMN39
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
ACT
2605 - Garran - The Canberra Hospital
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT06892522
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM (
M25-059
)
CELMoD agent
Carfilzomib
Daratumumab
Dexamethasone
Etentamig
Iberdomide
Lenalidomide
Mezigdomide
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
cancer therapy
cancer therapy,BCMA-targeting
cancer therapy,CD38-targeting
cancer therapy,cereblon-targeting
cancer therapy,proteasome-targeting
cereblon E3 ligase modulator
cereblon modulator
glucocorticoid
immuno-oncology therapy,BCMA-targeting
immuno-oncology therapy,CD38-targeting
immunomodulatory imide drug
proteasome inhibitor
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
+ anti-CD38 monoclonal antibody
Multiple myeloma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6005 - West Perth - Perth Blood Institute
NCT06768489
Haem
Phase 1
Recruiting
A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma (
79635322MMY1002
)
anti-CD38 monoclonal antibody
immunomodulatory imide drug
trispecific T-cell engager,BCMA/GPRC5D-targeting
Multiple myeloma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
NCT06679101
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) (
DREAMM-10
)
anti-BCMA-immunoconjugate
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT06669247
Haem
Phase 1 / Phase 2
Recruiting
A First-in-Human (FIH) Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN7945, an Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma (
COSTIMM
)
bispecific CD38/CD28 antibody
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4217 - Benowa - Pindara Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06615479
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (
CA088-1007
)
autologous CAR-T cell therapy,GPRC5D-targeting
immunomodulatory imide drug
+ anti-CD38 monoclonal antibody
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05862012
Haem
Phase 1
Recruiting
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma (
ISB-2001-101
)
trispecific T-cell engager,BCMA/CD38-targeting
Multiple myeloma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT05669989
Haem
Phase 2
Enrolling by invitation
International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental Study (
LTS17704
)
anti-CD38 monoclonal antibody
Multiple myeloma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT05623020
Haem
Phase 3
Recruiting
AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (
MagnetisMM-6
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
QLD
4217 - Benowa - Pindara Private Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NCT05552222
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy (
MajesTEC-7
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05020236
Haem
Phase 3
Recruiting
AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR (
MAGNETISMM-5
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04973605
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) (
BGB-11417-105
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
ACT
2605 - Garran - The Canberra Hospital
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
WA
6000 - Perth - Royal Perth Hospital
NCT04910568
Haem
Phase 1
Recruiting
An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone or Cevostamab Plus Daratumumab and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (
CAMMA-1
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,FcRH5-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3004 - Melbourne, Southbank - Alfred Health
NCT04643002
Haem
Phase 1 / Phase 2
Recruiting
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol (
ACT16482
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
ACTRN12624001468516
Haem
Phase 2
Not yet recruiting
A phase 2 study of the feasibility and efficacy of at home patient administered subcutaneous daratumumab in patients with relapsed multiple myeloma (
Dara@Home
)
anti-CD38 monoclonal antibody
Multiple myeloma
ACTRN12622000856718
Haem
Phase 1 / Phase 2
Not yet recruiting
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study assessing safety and tolerability of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma (
ISB-1442-101
)
bispecific CD38/CD47 antibody
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT07217184
Haem
Phase 1 / Phase 2
Active not recruiting
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5- Sub-study 5 - Belantamab Mafodotin and Isatuximab in Combination (
208887-Sub-Study-5
)
anti-BCMA-immunoconjugate
anti-CD38 monoclonal antibody
Multiple myeloma
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (19)
Not yet recruiting (3)
Enrolling by invitation (1)
Active not recruiting (1)
Recruitment Country and State
VIC (22)
NSW (17)
QLD (12)
WA (11)
SA (4)
NZ (3)
ACT (2)
TAS (1)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (8)
Phase 2 (2)
Phase 3 (10)
Trial Type
Haem (24)
Cancer Therapy Class
CD38
100%
cereblon
75%
BCMA
46%
proteasome
42%
IL-2
8%
Bcl2
8%
GPRC5D
8%
CD47
8%
CD28
4%
PD-1
4%
PD-1/PD-L1
4%
FcRH5
4%
IL-6
4%
ROCK2
4%
TGF-beta
4%
Facility
3065 - Fitzroy - St Vincent's Hospital Melbourne (14)
3004 - Melbourne, Southbank - Alfred Health (11)
2500 - Wollongong - Wollongong Hospital (6)
3000 - Melbourne - Peter MacCallum Cancer Centre (6)
3121 - Richmond - Epworth Freemasons Hospital (6)
4217 - Benowa - Pindara Private Hospital (6)
2050 - Camperdown - Chris O'Brien Lifehouse (6)
2170 - Liverpool - Liverpool Hospital (5)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
3002 - East Melbourne - Epworth Freemasons (4)
6150 - Murdoch - Fiona Stanley Hospital (4)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (3)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
3168 - Clayton - Monash Medical Centre (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
2139 - Concord - Concord Repatriation General Hospital (2)
6005 - West Perth - Perth Blood Institute (2)
4215 - Southport - Gold Coast University Hospital (2)
2605 - Garran - The Canberra Hospital (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (2)
3066 - Epping - Northern Hospital (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
6009 - Nedlands - Linear Clinical Research (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
NZ.0622 - Takapuna - North Shore Hospital (2)
NZ.3210 - Hamilton - Waikato Hospital (2)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
6000 - Perth - Royal Perth Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
7000 - Hobart - Royal Hobart Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Multiple myeloma
Plasma cell disorder
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy